Nanotechnology in Drug Discovery

Nanomaterials, a category of materials with a dimension in the nanometric range (1 nm-100 nm), were first recognized in 1959. They have unique physical, chemical, and mechanical properties, with nanoparticle size affecting properties like melting temperature, ionization potential, colour, electron affinity, electrical conductivity, and magnetism which is different from their bulk material. Nanotechnology improves biomarker development and aids in developing more sensitive treatments in medicine using nanodevices which enhances drug discovery by improving the understanding of biological processes, disease mechanisms, and signalling pathways. This chapter provides an overview of nanomaterials and examines their distinct properties. The key top-down and bottom-up methods for synthesizing nanomaterials are also explained along with specific examples. The chapter will also include a summary of several nanoparticle characterization methods and the attributes associated with each method. In addition, comprehensive information about advanced devices that have been inspired by nanotechnology to increase the efficiency of the drug development process through a better understanding of the biological mechanisms underlying diseases, signalling pathways, and the precise effects of medications have also been discussed. The chapter will conclude by outlining the advantages and challenges of using nanotechnology in drug development and treatment.

Nanotechnology plays a key role in the development of new drugs, from start to end through target identification, lead identification, lead optimization, and synthesis of active pharmaceutical ingredients (API) as well. Nanodevices and nanoparticles have been extensively utilized in discovering new drug targets in illness sites or blood and for swift screening of interactions of molecular compounds with therapeutic targets for lead identification/optimization. In addition, API development employing nanoparticle catalysts to expedite the drug development process and investigating pure nanomaterials as drugs are two further areas on which the pharmaceutical industry is concentrating. This chapter will go into great detail on how nanotechnology is used in the drug development process, starting with the identification of drug targets, moving on to the identification and optimization of leads, and concluding with the synthesis of API.

Nanomaterials, with their unique therapeutic traits such as antioxidant, antiinflammatory, antibacterial, antiviral, and anticancer properties, can be used as drug candidates to treat a wide range of diseases. Nano complexes like dendrimers, carbon nanotubes, fullerenes, graphene-based nanomaterials, carbon quantum dots, nanohydrogels, peptide nanostructures, MXenes, Silicene, and Antimonene have been distinguished by researchers, among the many nanomaterials because of their lower toxicity, ease of tuning to the desired end use, complex interactions with biological macromolecules, and solubility properties. This chapter will present the most recent research details on nanomaterials that have been developed as therapeutic candidates to treat a number of illnesses.

The development of ideal, secure, efficient, non-invasive drug delivery systems is now a top priority in this field of drug delivery. Nanoparticles are being employed more frequently for effective medication delivery, exerting the desired therapeutic effect at the expected site of action with the least amount of activity or volume loss. Size, surface chemistry, biological destiny, toxicity, in vivo dispersion, and targeting capabilities all play a role in these systems. The stability and interactions of nanoparticles with cells are regulated by their surface chemistry, and they can access a greater variety of targets. The development of nano-drug delivery systems has opened up new avenues for the treatment and prevention of disease, as well as for enhancing pharmacological properties, enhancing targeting, overcoming drug resistance, and lowering immunogenicity and toxicity. This chapter will first discuss the desirable characteristics of an effective drug delivery system and will cover recent developments in nano drug delivery systems used in clinical research, including dendrimers, solid lipid nanoparticles, nanogels, nanoemulsions, polymeric micelles, and polymer nanofibers.

Gaining insight into the process that ingested nanoparticles/nanodrugs is crucial to maximize therapeutic advantages and avoid side effects. In the process of drug development, it is critical to consider how nanodrugs are ingested, how they interact with body fluids, how particles are absorbed by cells, and how they are eliminated to achieve effective treatments. In addition, consideration of the toxicity of the ingested nanoparticles is of utmost significance. Hence the fate of ingested nanoparticles within the body will be covered in this chapter, including ingestion, endocytosis, exocytosis, and lastly the toxicity of the ingested NPs in vivo and in vitro. Initially, the chapter will brief about how the ingested nanoparticles undergo interactions with proteins in body fluids to form a protein corona and then will discuss comprehensively the different endocytic routes. Then the nanoparticle’s excretion from cells which is essential for preserving homeostasis and receptor function will be discussed. Finally, the toxicity such as DNA damage, protein damage, cell membrane damage, oxidative stress, inflammation, impaired protein synthesis, deregulated cellular functions, and neurotoxicity of some commonly used nanoparticles will be outlined.

Nanopharmaceuticals necessitate rigorous, costly testing to address safety concerns, including cytotoxic effects. The lack of toxicity testing protocols and understanding of the interactions of nanomaterials make it difficult to make accurate assessments of health risks. To meet the purpose of regulating and monitoring nano products in pharmaceuticals, various nations have devised their suitable regulatory processes. Approximately two decades are required for drug development, which includes drug discovery, clinical testing, and production approval. However, only when a novel pharmaceutical product can be mass manufactured in industrially substantial quantities is its development considered to be accomplished. At present, nanodrugs have already been introduced successfully to the market, demonstrating their future potential. This chapter will provide comprehensive details about the drug development process covering regulations, development, and commercialization of nano-based drugs

By enhancing drug administration and diagnostics, nanotechnology is transforming the healthcare industry. Novel approaches to drug design are being driven by combining cutting-edge technologies such as nanorobots and artificial intelligence. Healthcare can benefit from the potential of nanotechnology through the development of multifunctional nanotherapeutics, which could close gaps in the current therapeutic field.

Powered by integrated circuits, sensors, and data storage, nanorobots can increase efficiency and lessen systemic effects while follow-up care for cancer patients is made simpler by nanosensors. Additionally, nanotherapeutics have gained their way in developing novel therapeutics to overcome cancer drug resistance by targeting the mechanisms that induce the drug resistance. Another upcoming field in nanomedicine is the utilization of 3D printing techniques in order to create solid dosage forms based on nanomedicine. By enabling flexible design and on-demand manufacture of customized dosages, enhancing bioavailability, and other attributes, 3D printing technology has revolutionized the pharmaceutical industry. The futuristic applications of nanotechnology hybridized with novel techniques will be discussed in this chapter.